US FDA approves Pfizer's RSV vaccine for adults at increased risk of the disease
The U.S. Food and Drug Administration on Tuesday approved Pfizer's RSV vaccine for the prevention of lower respiratory tract ...
biopharma-reporter2d
The FDA has approved Pfizer’s RSV vaccine Abrysvo for adults aged 18 to 59
The US pharma giant Pfizer recently announced that its respiratory syncytial virus (RSV) vaccine Abrysvo has received FDA ...
FiercePharma2d
GSK answers Pfizer's RSV approval with data targeting matching nod in younger adults
“These promising data add to the evidence supporting GSK’s RSV vaccine and could help expand protection to more adults at ...
BioPharma Dive3d
Pfizer’s RSV vaccine cleared by FDA for use in some younger adults
Approval of Pfizer's Abrysvo in certain adults aged 18 to 59 years old will substantially expand the number of people ...
U.S. FDA Approves Pfizer’s RSV Vaccine ABRYSVO® for Adults Aged 18 to 59 at Increased Risk for Disease
Pfizer Inc. (NYSE: PFE) announced today that the U.S. Food and Drug Administration (FDA) has approved ABRYSVO® (Respiratory ...
Medpage Today on MSN3d
FDA Expands Approval of RSV Vaccine Abrysvo to Include All At-Risk Adults
The FDA expanded the approval of the bivalent RSV prefusion F (RSVpreF) vaccine (Abrysvo) to include the prevention of lower ...
Pfizer Receives FDA Approval for RSV Vaccine
Abrysvo can prevent lower respiratory tract disease caused by RSV for people between the ages of 18 and 59 who are at ...
FiercePharma3d
FDA approves Pfizer's RSV shot Abrysvo for all at-risk adults
While it’s a win for Pfizer over GSK and its RSV vaccine Arexvy, which is approved for those 50 and older, it’s difficult to ...
The Pharma Letter3d
New FDA approval for Pfizer’s RSV vaccine Abrysvo
The US Food and Drug Administration (FDA) yesterday approved Abrysvo (respiratory syncytial virus vaccine). Developed and ...
McKnight's Long-Term Care News2d
FDA OKs Pfizer’s RSV vaccine for some adults under 60
On Tuesday, the US Food and Drug Administration approved Pfizer’s respiratory syncytial virus (RSV) vaccine, Abrysvo, for ...
Just After Pfizer's RSV Vaccine Approval For Younger Adults, GSK Layouts Encouraging Preliminary Data Showing Potential For Use In Larger Population
GSK unveils new Arexvy data showing strong protection in adults 18-49 at risk for RSV. The vaccine could broaden coverage for ...
Pfizer Receives Expanded FDA Approval for RSV Vaccine
Abrysvo is the first vaccine for the respiratory syncytial virus that is indicated for adults younger than 50, the drugmaker ...